Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R)
Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Nef, Holger [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016transfer abstract |
|---|
| Umfang: |
4 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Cardiovascular revascularization medicine - Villemagne, Victor ELSEVIER, 2012, CRM, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:17 ; year:2016 ; number:1 ; pages:34-37 ; extent:4 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.carrev.2015.09.002 |
|---|
| Katalog-ID: |
ELV035124520 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035124520 | ||
| 003 | DE-627 | ||
| 005 | 20230625203139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.carrev.2015.09.002 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016005000013.pica |
| 035 | |a (DE-627)ELV035124520 | ||
| 035 | |a (ELSEVIER)S1553-8389(15)00230-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.68 |2 bkl | ||
| 100 | 1 | |a Nef, Holger |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) |
| 264 | 1 | |c 2016transfer abstract | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. | ||
| 520 | |a Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. | ||
| 700 | 1 | |a Wiebe, Jens |4 oth | |
| 700 | 1 | |a Achenbach, Stefan |4 oth | |
| 700 | 1 | |a Münzel, Thomas |4 oth | |
| 700 | 1 | |a Naber, Christoph |4 oth | |
| 700 | 1 | |a Richardt, Gert |4 oth | |
| 700 | 1 | |a Mehilli, Julinda |4 oth | |
| 700 | 1 | |a Wöhrle, Jochen |4 oth | |
| 700 | 1 | |a Neumann, Till |4 oth | |
| 700 | 1 | |a Biermann, Janine |4 oth | |
| 700 | 1 | |a Zahn, Ralf |4 oth | |
| 700 | 1 | |a Kastner, Johannes |4 oth | |
| 700 | 1 | |a Schmermund, Axel |4 oth | |
| 700 | 1 | |a Pfannebecker, Thomas |4 oth | |
| 700 | 1 | |a Schneider, Steffen |4 oth | |
| 700 | 1 | |a Limbourg, Tobias |4 oth | |
| 700 | 1 | |a Hamm, Christian W. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Villemagne, Victor ELSEVIER |t Cardiovascular revascularization medicine |d 2012 |d CRM |g Amsterdam [u.a.] |w (DE-627)ELV000085782 |
| 773 | 1 | 8 | |g volume:17 |g year:2016 |g number:1 |g pages:34-37 |g extent:4 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.carrev.2015.09.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.68 |j Gerontologie |j Geriatrie |q VZ |
| 951 | |a AR | ||
| 952 | |d 17 |j 2016 |e 1 |h 34-37 |g 4 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
h n hn |
|---|---|
| matchkey_str |
nefholgerwiebejensachenbachstefanmnzelth:2016----:vlainfhsotnlntrsftadhrpotoeotevrlmsltnboeobbeaclrcfodytmnainsihooayreytnssai |
| hierarchy_sort_str |
2016transfer abstract |
| bklnumber |
44.68 |
| publishDate |
2016 |
| allfields |
10.1016/j.carrev.2015.09.002 doi GBVA2016005000013.pica (DE-627)ELV035124520 (ELSEVIER)S1553-8389(15)00230-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.68 bkl Nef, Holger verfasserin aut Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) 2016transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. Wiebe, Jens oth Achenbach, Stefan oth Münzel, Thomas oth Naber, Christoph oth Richardt, Gert oth Mehilli, Julinda oth Wöhrle, Jochen oth Neumann, Till oth Biermann, Janine oth Zahn, Ralf oth Kastner, Johannes oth Schmermund, Axel oth Pfannebecker, Thomas oth Schneider, Steffen oth Limbourg, Tobias oth Hamm, Christian W. oth Enthalten in Elsevier Science Villemagne, Victor ELSEVIER Cardiovascular revascularization medicine 2012 CRM Amsterdam [u.a.] (DE-627)ELV000085782 volume:17 year:2016 number:1 pages:34-37 extent:4 https://doi.org/10.1016/j.carrev.2015.09.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 17 2016 1 34-37 4 045F 610 |
| spelling |
10.1016/j.carrev.2015.09.002 doi GBVA2016005000013.pica (DE-627)ELV035124520 (ELSEVIER)S1553-8389(15)00230-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.68 bkl Nef, Holger verfasserin aut Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) 2016transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. Wiebe, Jens oth Achenbach, Stefan oth Münzel, Thomas oth Naber, Christoph oth Richardt, Gert oth Mehilli, Julinda oth Wöhrle, Jochen oth Neumann, Till oth Biermann, Janine oth Zahn, Ralf oth Kastner, Johannes oth Schmermund, Axel oth Pfannebecker, Thomas oth Schneider, Steffen oth Limbourg, Tobias oth Hamm, Christian W. oth Enthalten in Elsevier Science Villemagne, Victor ELSEVIER Cardiovascular revascularization medicine 2012 CRM Amsterdam [u.a.] (DE-627)ELV000085782 volume:17 year:2016 number:1 pages:34-37 extent:4 https://doi.org/10.1016/j.carrev.2015.09.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 17 2016 1 34-37 4 045F 610 |
| allfields_unstemmed |
10.1016/j.carrev.2015.09.002 doi GBVA2016005000013.pica (DE-627)ELV035124520 (ELSEVIER)S1553-8389(15)00230-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.68 bkl Nef, Holger verfasserin aut Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) 2016transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. Wiebe, Jens oth Achenbach, Stefan oth Münzel, Thomas oth Naber, Christoph oth Richardt, Gert oth Mehilli, Julinda oth Wöhrle, Jochen oth Neumann, Till oth Biermann, Janine oth Zahn, Ralf oth Kastner, Johannes oth Schmermund, Axel oth Pfannebecker, Thomas oth Schneider, Steffen oth Limbourg, Tobias oth Hamm, Christian W. oth Enthalten in Elsevier Science Villemagne, Victor ELSEVIER Cardiovascular revascularization medicine 2012 CRM Amsterdam [u.a.] (DE-627)ELV000085782 volume:17 year:2016 number:1 pages:34-37 extent:4 https://doi.org/10.1016/j.carrev.2015.09.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 17 2016 1 34-37 4 045F 610 |
| allfieldsGer |
10.1016/j.carrev.2015.09.002 doi GBVA2016005000013.pica (DE-627)ELV035124520 (ELSEVIER)S1553-8389(15)00230-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.68 bkl Nef, Holger verfasserin aut Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) 2016transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. Wiebe, Jens oth Achenbach, Stefan oth Münzel, Thomas oth Naber, Christoph oth Richardt, Gert oth Mehilli, Julinda oth Wöhrle, Jochen oth Neumann, Till oth Biermann, Janine oth Zahn, Ralf oth Kastner, Johannes oth Schmermund, Axel oth Pfannebecker, Thomas oth Schneider, Steffen oth Limbourg, Tobias oth Hamm, Christian W. oth Enthalten in Elsevier Science Villemagne, Victor ELSEVIER Cardiovascular revascularization medicine 2012 CRM Amsterdam [u.a.] (DE-627)ELV000085782 volume:17 year:2016 number:1 pages:34-37 extent:4 https://doi.org/10.1016/j.carrev.2015.09.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 17 2016 1 34-37 4 045F 610 |
| allfieldsSound |
10.1016/j.carrev.2015.09.002 doi GBVA2016005000013.pica (DE-627)ELV035124520 (ELSEVIER)S1553-8389(15)00230-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.68 bkl Nef, Holger verfasserin aut Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) 2016transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. Wiebe, Jens oth Achenbach, Stefan oth Münzel, Thomas oth Naber, Christoph oth Richardt, Gert oth Mehilli, Julinda oth Wöhrle, Jochen oth Neumann, Till oth Biermann, Janine oth Zahn, Ralf oth Kastner, Johannes oth Schmermund, Axel oth Pfannebecker, Thomas oth Schneider, Steffen oth Limbourg, Tobias oth Hamm, Christian W. oth Enthalten in Elsevier Science Villemagne, Victor ELSEVIER Cardiovascular revascularization medicine 2012 CRM Amsterdam [u.a.] (DE-627)ELV000085782 volume:17 year:2016 number:1 pages:34-37 extent:4 https://doi.org/10.1016/j.carrev.2015.09.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 17 2016 1 34-37 4 045F 610 |
| language |
English |
| source |
Enthalten in Cardiovascular revascularization medicine Amsterdam [u.a.] volume:17 year:2016 number:1 pages:34-37 extent:4 |
| sourceStr |
Enthalten in Cardiovascular revascularization medicine Amsterdam [u.a.] volume:17 year:2016 number:1 pages:34-37 extent:4 |
| format_phy_str_mv |
Article |
| bklname |
Gerontologie Geriatrie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Cardiovascular revascularization medicine |
| authorswithroles_txt_mv |
Nef, Holger @@aut@@ Wiebe, Jens @@oth@@ Achenbach, Stefan @@oth@@ Münzel, Thomas @@oth@@ Naber, Christoph @@oth@@ Richardt, Gert @@oth@@ Mehilli, Julinda @@oth@@ Wöhrle, Jochen @@oth@@ Neumann, Till @@oth@@ Biermann, Janine @@oth@@ Zahn, Ralf @@oth@@ Kastner, Johannes @@oth@@ Schmermund, Axel @@oth@@ Pfannebecker, Thomas @@oth@@ Schneider, Steffen @@oth@@ Limbourg, Tobias @@oth@@ Hamm, Christian W. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000085782 |
| dewey-sort |
3610 |
| id |
ELV035124520 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035124520</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625203139.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.carrev.2015.09.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016005000013.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035124520</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1553-8389(15)00230-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.68</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nef, Holger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wiebe, Jens</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Achenbach, Stefan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Münzel, Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Naber, Christoph</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richardt, Gert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mehilli, Julinda</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wöhrle, Jochen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neumann, Till</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Biermann, Janine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zahn, Ralf</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kastner, Johannes</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmermund, Axel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pfannebecker, Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schneider, Steffen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Limbourg, Tobias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamm, Christian W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Villemagne, Victor ELSEVIER</subfield><subfield code="t">Cardiovascular revascularization medicine</subfield><subfield code="d">2012</subfield><subfield code="d">CRM</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000085782</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:34-37</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.carrev.2015.09.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.68</subfield><subfield code="j">Gerontologie</subfield><subfield code="j">Geriatrie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="h">34-37</subfield><subfield code="g">4</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Nef, Holger |
| spellingShingle |
Nef, Holger ddc 610 bkl 44.68 Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) |
| authorStr |
Nef, Holger |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000085782 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.68 bkl Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) |
| topic |
ddc 610 bkl 44.68 |
| topic_unstemmed |
ddc 610 bkl 44.68 |
| topic_browse |
ddc 610 bkl 44.68 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j w jw s a sa t m tm c n cn g r gr j m jm j w jw t n tn j b jb r z rz j k jk a s as t p tp s s ss t l tl c w h cw cwh |
| hierarchy_parent_title |
Cardiovascular revascularization medicine |
| hierarchy_parent_id |
ELV000085782 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Cardiovascular revascularization medicine |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000085782 |
| title |
Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) |
| ctrlnum |
(DE-627)ELV035124520 (ELSEVIER)S1553-8389(15)00230-4 |
| title_full |
Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) |
| author_sort |
Nef, Holger |
| journal |
Cardiovascular revascularization medicine |
| journalStr |
Cardiovascular revascularization medicine |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
34 |
| author_browse |
Nef, Holger |
| container_volume |
17 |
| physical |
4 |
| class |
610 610 DE-600 610 VZ 44.68 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Nef, Holger |
| doi_str_mv |
10.1016/j.carrev.2015.09.002 |
| dewey-full |
610 |
| title_sort |
evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: rationale and design of the german–austrian absorb registry (gabi-r) |
| title_auth |
Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) |
| abstract |
Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. |
| abstractGer |
Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. |
| abstract_unstemmed |
Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
1 |
| title_short |
Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R) |
| url |
https://doi.org/10.1016/j.carrev.2015.09.002 |
| remote_bool |
true |
| author2 |
Wiebe, Jens Achenbach, Stefan Münzel, Thomas Naber, Christoph Richardt, Gert Mehilli, Julinda Wöhrle, Jochen Neumann, Till Biermann, Janine Zahn, Ralf Kastner, Johannes Schmermund, Axel Pfannebecker, Thomas Schneider, Steffen Limbourg, Tobias Hamm, Christian W. |
| author2Str |
Wiebe, Jens Achenbach, Stefan Münzel, Thomas Naber, Christoph Richardt, Gert Mehilli, Julinda Wöhrle, Jochen Neumann, Till Biermann, Janine Zahn, Ralf Kastner, Johannes Schmermund, Axel Pfannebecker, Thomas Schneider, Steffen Limbourg, Tobias Hamm, Christian W. |
| ppnlink |
ELV000085782 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.carrev.2015.09.002 |
| up_date |
2024-07-06T16:44:45.948Z |
| _version_ |
1803848815426404352 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035124520</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625203139.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.carrev.2015.09.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016005000013.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035124520</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1553-8389(15)00230-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.68</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nef, Holger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2–4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wiebe, Jens</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Achenbach, Stefan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Münzel, Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Naber, Christoph</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richardt, Gert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mehilli, Julinda</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wöhrle, Jochen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neumann, Till</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Biermann, Janine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zahn, Ralf</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kastner, Johannes</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmermund, Axel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pfannebecker, Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schneider, Steffen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Limbourg, Tobias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamm, Christian W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Villemagne, Victor ELSEVIER</subfield><subfield code="t">Cardiovascular revascularization medicine</subfield><subfield code="d">2012</subfield><subfield code="d">CRM</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000085782</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:34-37</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.carrev.2015.09.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.68</subfield><subfield code="j">Gerontologie</subfield><subfield code="j">Geriatrie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="h">34-37</subfield><subfield code="g">4</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399913 |